TBC1D10C

Across TCGA pan-cancer cohorts, TBC1D10C Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TBC1D10C data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher TBC1D10C Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated TBC1D10C expression acts as an unfavorable survival marker.

BLCA, MESO, and SKCM are the cancer types where TBC1D10C Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	All	0.051	0.720	<.001	30	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
SKCM	OS	Median	IV	0.415	0.861	.014	3	view →
LUSC	OS	Median	All	0.171	0.401	.048	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TBC1D10C–BLCA (OS)

Open the BLCA breakdown →